"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 20 | 20 |
| 2004 | 0 | 68 | 68 |
| 2005 | 0 | 71 | 71 |
| 2006 | 1 | 58 | 59 |
| 2007 | 0 | 69 | 69 |
| 2008 | 1 | 79 | 80 |
| 2009 | 2 | 111 | 113 |
| 2010 | 0 | 91 | 91 |
| 2011 | 0 | 118 | 118 |
| 2012 | 1 | 87 | 88 |
| 2013 | 2 | 110 | 112 |
| 2014 | 0 | 119 | 119 |
| 2015 | 0 | 128 | 128 |
| 2016 | 0 | 129 | 129 |
| 2017 | 0 | 90 | 90 |
| 2018 | 0 | 131 | 131 |
| 2019 | 0 | 110 | 110 |
| 2020 | 0 | 111 | 111 |
| 2021 | 0 | 93 | 93 |
| 2022 | 0 | 34 | 34 |
| 2023 | 0 | 45 | 45 |
| 2024 | 0 | 84 | 84 |
| 2025 | 0 | 18 | 18 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
PRDM1 Is a Key Regulator of the NKT-cell Central Memory Program and Effector Function. Cancer Immunol Res. 2025 Apr 02; 13(4):577-590.
-
Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer. Cancer Discov. 2025 Apr 02; 15(4):818-837.
-
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. Clin Cancer Res. 2025 Mar 17; 31(6):1069-1081.
-
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation. Clin Cancer Res. 2025 Mar 17; 31(6):1057-1068.
-
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia. Blood. 2025 Mar 13; 145(11):1182-1194.
-
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation. Blood. 2025 Mar 06; 145(10):1047-1060.
-
Gain-of-Function Chromatin Remodeling Activity of Oncogenic FOXL2C134W Reprograms Glucocorticoid Receptor Occupancy to Drive Granulosa Cell Tumors. Cancer Res. 2025 Mar 03; 85(5):875-893.
-
A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function. Cancer Res Commun. 2025 Mar 01; 5(3):527-548.
-
ZP4: A novel target for CAR-T cell therapy in triple negative breast cancer. Mol Ther. 2025 Apr 02; 33(4):1621-1641.
-
MAGE-A4 induces non-small cell lung cancer and tumor-promoting plasma cell accumulation. Sci Adv. 2025 Feb 14; 11(7):eads4227.